• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nuvalent Inc.

    4/26/24 4:10:32 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email
    DEFA14A 1 nuvl-defa14a-2024.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under § 240.14a-12

    NUVALENT, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

     

    img237602011_0.jpg 

     

    Your Vote Counts! NUVALENT, INC. 2024 Annual Meeting Vote by June 11, 2024 11:59 PM ET NUVALENT, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE, MA 02142 V43630-P02661 You invested in NUVALENT, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2024. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting by May 29, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2024 1:00 PM ET Virtually at: www.virtualshareholdermeeting.com/NUVL2024 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img237602011_1.jpg 

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of the following nominees as Class III directors: Nominees: 1a. Emily Drabant Conley, Ph.D. 1b. Sapna Srivastava, Ph.D. 1c. Cameron Wheeler, Ph.D. 2. To approve, on an advisory basis, the compensation paid to our named executive officers. 3. To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation paid to our named executive officers. 4. To ratify the appointment of KPMG LLP as Nuvalent, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2024. NOTE: The proxies are authorized to vote in their discretion upon such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof. Fpr For For For For Year Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V43631-P02661

     


    Get the next $NUVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/12/2025$126.00Buy
    Canaccord Genuity
    10/16/2025$115.00Buy
    Stifel
    10/15/2025$135.00Overweight
    Cantor Fitzgerald
    9/4/2025$122.00Buy
    Guggenheim
    9/3/2025$105.00Outperform
    Raymond James
    8/19/2025$112.00Overweight
    Piper Sandler
    3/14/2025$100.00Neutral → Buy
    UBS
    More analyst ratings

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC. A live webcast will be available in the Investors section of Nuvalent's website at www.nuvalent.com,

    2/5/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

    FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m. PT CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage

    1/12/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PT in San Francisco.  A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation. About Nuva

    12/22/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    SEC Filings

    View All

    Nuvalent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    1/14/26 6:30:30 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Nuvalent Inc.

    S-3ASR - Nuvalent, Inc. (0001861560) (Filer)

    12/22/25 7:51:02 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Inc. filed SEC Form 8-K: Other Events

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    12/16/25 10:06:42 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Truist initiated coverage on Nuvalent

    Truist initiated coverage of Nuvalent with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nuvalent with a new price target

    Canaccord Genuity initiated coverage of Nuvalent with a rating of Buy and set a new price target of $126.00

    11/12/25 8:57:08 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Nuvalent with a new price target

    Stifel resumed coverage of Nuvalent with a rating of Buy and set a new price target of $115.00

    10/16/25 8:51:17 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Noci Darlene exercised 5,500 shares at a strike of $27.85 and sold $561,422 worth of shares (5,500 units at $102.08) (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    2/2/26 4:30:46 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Miller Deborah Ann sold $1,652,176 worth of shares (15,000 units at $110.15) and exercised 15,000 shares at a strike of $27.85 (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    1/23/26 4:31:29 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Pelish Henry E. was granted 17,500 shares and sold $501,753 worth of shares (5,160 units at $97.24), increasing direct ownership by 17% to 83,388 units (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    1/7/26 5:27:06 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

    Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

    8/7/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Appoints Christy Oliger to Board of Directors

    CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors. "Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and

    6/18/25 4:30:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Financials

    Live finance-specific insights

    View All

    Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

    In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectivelyNeladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing designCompany p

    11/17/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

    Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.

    11/14/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

    Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmarkIn the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of respo

    6/24/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:50:28 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:34:36 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    5/15/24 6:39:30 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care